{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nanoliposomal-Irinotecan&page=3", "query": { "intervention": "Nanoliposomal-Irinotecan", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 52, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nanoliposomal-Irinotecan&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nanoliposomal-Irinotecan&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T09:18:17.169Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02551991", "title": "Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "nal-IRI", "type": "DRUG" }, { "name": "5 fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2015-10-19", "completion_date": "2021-02-15", "has_results": true, "last_update_posted_date": "2022-10-10", "last_synced_at": "2026-10-07T09:18:17.169Z", "location_count": 29, "location_summary": "Mobile, Alabama • Avondale, Arizona • Phoenix, Arizona + 24 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Avondale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02551991" }, { "nct_id": "NCT04005339", "title": "NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Biliary Tract Cancer" ], "interventions": [ { "name": "Nanoliposomal Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2019-07-29", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-10-07T09:18:17.169Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Indianapolis, Indiana • St Louis, Missouri + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04005339" }, { "nct_id": "NCT04753216", "title": "Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Refractory Fallopian Tube Carcinoma", "Refractory Ovarian Carcinoma", "Refractory Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Irinotecan Sucrosofate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3, "start_date": "2021-03-16", "completion_date": "2021-10-25", "has_results": true, "last_update_posted_date": "2023-01-19", "last_synced_at": "2026-10-07T09:18:17.169Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04753216" }, { "nct_id": "NCT04731467", "title": "A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Non Small Cell Lung Cancer", "Pancreatic Cancer", "Ovarian Cancer", "Papillary Thyroid Cancer", "Melanoma", "Colorectal Adenocarcinoma" ], "interventions": [ { "name": "CM-24 and Nivolumab - Dose Escalation", "type": "DRUG" }, { "name": "CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion", "type": "DRUG" }, { "name": "CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion", "type": "DRUG" }, { "name": "Nivolumab, Nab paclitaxel and Gemcitabine - Expansion", "type": "DRUG" }, { "name": "Nivolumab and Nal-IRI/5-FU/LV - Expansion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Famewave Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2021-03-19", "completion_date": "2024-09-30", "has_results": false, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-10-07T09:18:17.169Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • New Haven, Connecticut + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04731467" }, { "nct_id": "NCT00364143", "title": "Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "IHL-305 (irinotecan liposome injection)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yakult Honsha Co., LTD", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2006-09", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2019-07-05", "last_synced_at": "2026-10-07T09:18:17.169Z", "location_count": 2, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00364143" }, { "nct_id": "NCT03883919", "title": "Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "Pancreas Cancer", "Cancer of the Pancreas" ], "interventions": [ { "name": "5-FU", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Liposomal Irinotecan", "type": "DRUG" }, { "name": "Paricalcitol", "type": "DRUG" }, { "name": "Serum and plasma blood samples", "type": "PROCEDURE" }, { "name": "Tumor biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2019-07-11", "completion_date": "2022-07-02", "has_results": false, "last_update_posted_date": "2022-10-05", "last_synced_at": "2026-10-07T09:18:17.169Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03883919" }, { "nct_id": "NCT07060014", "title": "NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Small Intestine Cancer", "Appendiceal Cancers" ], "interventions": [ { "name": "Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2026-09-18", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-07T09:18:17.169Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07060014" }, { "nct_id": "NCT06219941", "title": "AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Cancer", "Biliary Tract Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "AZD0901", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "l-leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Nanoliposomal Irinotecan", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2023-12-13", "completion_date": "2027-06-28", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-07T09:18:17.169Z", "location_count": 7, "location_summary": "Orange, California • Palo Alto, California • Santa Rosa, California + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06219941" }, { "nct_id": "NCT03368963", "title": "TAS102 in Combination With NAL-IRI in Advanced GI Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Adenocarcinoma", "Gastric Adenocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Non-Resectable Cholangiocarcinoma", "Stage IV Colorectal Cancer", "Stage IV Gastric Cancer", "Stage IV Pancreatic Cancer", "Stage IVA Colorectal Cancer", "Stage IVB Colorectal Cancer", "Stage III Colorectal Cancer", "Stage III Gastric Cancer", "Stage III Pancreatic Cancer", "Unresectable Digestive System Adenocarcinoma", "Unresectable Pancreatic Carcinoma" ], "interventions": [ { "name": "Nanoliposomal Irinotecan", "type": "DRUG" }, { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2018-01-30", "completion_date": "2025-11-28", "has_results": false, "last_update_posted_date": "2025-01-07", "last_synced_at": "2026-10-07T09:18:17.169Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03368963" }, { "nct_id": "NCT03861702", "title": "Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Pancreatic Carcinoma(LAPC)" ], "interventions": [ { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "Liposomal Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nelson Yee", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2020-09-02", "completion_date": "2024-09-27", "has_results": true, "last_update_posted_date": "2025-04-18", "last_synced_at": "2026-10-07T09:18:17.169Z", "location_count": 4, "location_summary": "Chicago, Illinois • Indianapolis, Indiana • New Brunswick, New Jersey + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03861702" } ] }